Peptides as multifunctional players in cancer therapy

참고문헌 (148)

1. Ladner, R. C., "Phage display-derived peptides as therapeutic alternatives to antibodies", Drug Disco, 9, pp.525~529 (2004)
2. Fosgerau, K., "Peptide therapeutics : current status and future directions", Drug Disco, 20, pp.122~128 (2015)
3. Blanco-Míguez, A., "From amino acid sequence to bioactivity : the biomedical potential of antitumor peptides", Protein Sci, 25, pp.1084~1095 (2016)
4. Wang, L., "Therapeutic peptides : current applications and future directions", Signal Transduct. Target Ther, 7, pp.48~ (2022)
5. Kessel, C., "Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies", Chem. Med. Chem, 4, pp.1364~1370 (2009)
6. Knittelfelder, R., "Mimotope vaccination–from allergy to cancer", Expert Opin. Biol. Ther, 9, pp.493~506 (2009)
7. Tong, A. H. Y., "A combined experimental and computational strategy to define protein interaction networks for peptide recognition modules", Science, 295, pp.321~324 (2002)
8. Liu, M., "Peptide-enabled targeted delivery systems for therapeutic applications", Front Bioeng. Biotechnol, 9, pp.701504~ (2021)
9. Chen, Y., "Sortase A-mediated cyclization of novel polycyclic RGD peptides for ανβ3 integrin targeting", Bioorg. Med Chem. Lett, 73, pp.128888~ (2022)
10. Echigo, H., "Development and evaluation of a theranostic probe with RGD peptide introduced platinum complex to enable tumor-specific accumulation", Bioorg. Med. Chem, 70, pp.116919~ (2022)
11. Kato, N., "Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes : Application of cyclic RGD peptide", Eur. J. Pharm. Sci, 176, pp.106239~ (2022)
12. Chen, K., "Integrin targeted delivery of chemotherapeutics", Theranostics, 1, pp.189~ (2011)
13. Sugahara, K. N., "Tissue-penetrating delivery of compounds and nanoparticles into tumors", Cancer cell, 16, pp.510~520 (2009)
14. Ruoslahti, E., "Tumor penetrating peptides for improved drug delivery", Adv. Drug Deliv. Rev, 110, pp.3~12 (2017)
15. Teesalu, T., "C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration", Proc. Natl Acad. Sci. USA, 106, pp.16157~16162 (2009)
16. Chen, T., "nRGD modified lycobetaine and octreotide combination delivery system to overcome multiple barriers and enhance anti-glioma efficacy", Colloids Surf. B, 156, pp.330~339 (2017)
17. Su, S., "iRGD-coupled responsive fluorescent nanogel for targeted drug delivery", Biomaterials, 34, pp.3523~3533 (2013)
18. Yu, K. -F., "The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells : in vitro and in vivo evaluation", Int J. Nanomed, 8, pp.2473~ (2013)
19. Fogal, V., "Mitochondrial", cell-surface protein p32, Cancer Res, pp.2008, 68[DOI]
20. Karmali, P. P., "Targeting of albumin-embedded paclitaxel nanoparticles to tumors", Nanomedicine, 5, pp.73~82 (2009)
21. Hardwick, J. S., "Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling", Mol. Cancer Ther, 4, pp.413~425 (2005)
22. Yu, D. -H., "Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature", Biomaterials, 31, pp.2278~2292 (2010)
23. Obiri, N., "Expression of high-affinity IL-4receptors on human melanoma, ovarian and breast carcinoma cells", Clin. Exp. Immunol, 95, pp.148~155 (1994)
24. Kawakami, K., "Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells", Cancer Res, 60, pp.2981~2987 (2000)
25. Kawakami, M., "Interleukin 4 receptor on human lung cancer : a molecular target for cytotoxin therapy", Clin. Cancer Res, 8, pp.3503~3511 (2002)
26. Kim, J. -H., "Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues", J. Control Release, 157, pp.493~499 (2012)
27. Chi, L., "Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells", J. Control Release, 209, pp.327~336 (2015)
28. Jeon, J. O., "Designed nanocage displaying ligand-specific peptide bunches for high affinity and biological activity", ACS Nano, 7, pp.7462~7471 (2013)
29. Guruprasath, P., "Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth", Biomaterials, 142, pp.101~111 (2017)
30. Namgung, R., "Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy", Nat. Commun, 5, pp.1~12 (2014)
31. de Groot, A. E., "Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotype", Neoplasia, 32, pp.100830~ (2022)
32. Bankaitis, K. V., "Targeting IL4", IL4R for the treatment of epithelial cancer metastasis, 2015, pp.32, 847~856
33. Figueiredo, P., "Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy", Acta Biomater, 133, pp.231~243 (2021)
34. Johnsen, K. B., "A comprehensive overview of exosomes as drug delivery vehicles—endogenous nanocarriers for targeted cancer therapy", Biochim Biophys. Acta Rev. Cancer, 1846, pp.75~87 (2014)
35. Alvarez-Erviti, L., "Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes", Nat. Biotechnol, 29, pp.341~345 (2011)
36. Tian, Y., "A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy", Biomaterials, 35, pp.2383~2390 (2014)
37. Ohno, S. -i, "Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells", Mol. Ther, 21, pp.185~191 (2013)
38. Morishita, M., "Enhanced class I tumor antigen presentation via cytosolic delivery of exosomal cargos by tumor-cell-derived exosomes displaying a pH-sensitive fusogenic peptide", Mol. Pharm, 14, pp.4079~4086 (2017)
39. Gunassekaran, G. R., "M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages", Biomaterials, 278, pp.121137~ (2021)
40. Zhan, Q., "Engineering blood exosomes for tumor-targeting efficient gene", chemo combination therapy, 2020, pp.10, 7889~
41. Cheng, H., "Chimeric peptide engineered exosomes for dual-stage light guided plasma membrane and nucleus targeted photodynamic therapy", Biomaterials, 211, pp.14~24 (2019)
42. Lim, W. A., "The principles of engineering immune cells to treat cancer", Cell, 168, pp.724~740 (2017)
43. Maus, M. V., "Making better chimeric antigen receptors for adoptive T-cell therapy", Clin. Cancer Res, 22, pp.1875~1884 (2016)
44. Gunassekaran, G. R., "Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma", Biomaterials, 159, pp.161~173 (2018)
45. Cheng, H., "Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell–selectin interaction kinetics", Biomaterials, 33, pp.5004~5012 (2012)
46. Sarkar, D., "Engineered cell homing", Blood, 118, pp.e184~e191 (2011)
47. Johnstone, S. A., "In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines", Anticancer Drug Des, 15, pp.151~160 (2000)
48. Luan, X., "Cytotoxic and antitumor peptides as novel chemotherapeutics", Nat. Prod. Rep, 38, pp.7~17 (2021)
49. Mai, J. C., "A proapoptotic peptide for the treatment of solid tumors", Cancer Res, 61, pp.7709~7712 (2001)
50. Dufort, S., "Targeted delivery of a proapoptotic peptide to tumors in vivo", J. Drug Target, 19, pp.582~588 (2011)
51. Jin, Y., "Nanosystem composed with MSNs, gadolinium, liposome and cytotoxic peptides for tumor theranostics", Colloids Surf. B, 151, pp.240~248 (2017)
52. Ellerby, H. M., "Anti-cancer activity of targeted pro-apoptotic peptides", Nat. Med, 5, pp.1032~1038 (1999)
53. Permpoon, U., "Inhibition of tumor growth against chemoresistant cholangiocarcinoma by a proapoptotic peptide targeting interleukin-4 receptor", Mol. Pharm, 17, pp.4077~4088 (2020)
54. Vadevoo, S. M. P., "IL4 receptor–targeted proapoptotic peptide blocks tumor growth and metastasis by enhancing antitumor immunity anticancer activity of IL4R-targeted proapoptotic peptide", Mol. Cancer Ther, 16, pp.2803~2816 (2017)
55. Khan, F., "Identification of novel CD44v6-binding peptides that block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in mice", Theranostics, 11, pp.1326~ (2021)
56. Fantin, V. R., "A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells", Cancer Res, 65, pp.6891~6900 (2005)
57. Arap, W., "Targeting the prostate for destruction through a vascular address", Proc. Natl Acad. Sci. USA, 99, pp.1527~1531 (2002)
58. Jung, H. -K., "Bladder tumor-targeted delivery of pro-apoptotic peptide for cancer therapy", J. Control Release, 235, pp.259~267 (2016)
59. Sri Murugan Poongkavithai Vadevoo, "Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy", Archives of Pharmacal Research, 42(2), pp.150~158 (2019), 대한약학회[DOI]
60. Yamasaki, K., "Antimicrobial peptides in human skin disease", Eur. J. Dermatol, 18, pp.11~21 (2008)
61. Leuschner, C., "Membrane disrupting lytic peptides for cancer treatments", Curr. Pharm. Des, 10, pp.2299~2310 (2004)
62. Yang, N., "Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide", J. Pept. Sci, 9, pp.300~311 (2003)
63. Han, J. -H., "Noxa mitochondrial targeting domain induces necrosis via VDAC2 and mitochondrial catastrophe", Cell Death Dis, 10, pp.1~13 (2019)
64. Warren, P., "In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two γ-linked glutamate residues at the COOH terminus", Cancer Res, 61, pp.6783~6787 (2001)
65. Ersahin, D., "Targeted radionuclide therapy", Cancers, 3, pp.3838~3855 (2011)
66. Costa, F., "Octreotide–a review of its use in treating neuroendocrine tumours", Eur. Endocrinol, 10, pp.70~ (2014)
67. Bodei, L., "Peptide receptor radionuclide therapy(PRRT)of neuroendocrine tumors with somatostatin analogues", Eur. Rev. Med Pharm. Sci, 14, pp.347~351 (2010)
68. octreotide : which peptide is preferable for PRRT? Eur, "J. Nucl. Med. Mol. Imaging", 2006, 1346~1351
69. Van de Wiele, C., "Biodistribution and dosimetry of 99mTc-RP527, a gastrinreleasing peptide(GRP)agonist for the visualization of GRP receptor-expressing malignancies", J. Nucl. Med, 42, pp.1722~1727 (2001)
70. Laverman, P., "Targeting of a CCK2 receptor splice variant with 111Inlabelled cholecystokinin-8(CCK8)and 111In-labelled minigastrin", Eur. J. Nucl. Med. Mol. Imaging, 35, pp.386~392 (2008)
71. La Manna, S., "Peptides as therapeutic agents for inflammatory-related diseases", Int J. Mol. Sci, 19, pp.2714~ (2018)
72. do Pazo, C., "The oncology market for antibody-drug conjugates", Nat. Rev. Drug Discov, 20, pp.583~584 (2021)
73. Hoppenz, P., "Peptide-drug conjugates and their targets in advanced cancer therapies", Front Chem, 8, pp.571~ (2020)
74. Chavda, V. P., "Peptide-drug conjugates : a new hope for cancer management", Molecules, 27, pp.7232~ (2022)
75. Raza Naqvi, S. A., "Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo", Cancer Biother Radiopharm, 25, pp.89~95 (2010)
76. van Duijnhoven, S. M., "Tumor targeting of MMP-2", 9 activatable cell-penetrating imaging probes is caused by tumorindependent activation, 2011, pp.52, 279~286
77. Szabó, I., "Development of an oxime bond containing daunorubicingonadotropin-releasing hormone-III conjugate as a potential anticancer drug", Bioconjug Chem, 20, pp.656~665 (2009)
78. Lelle, M., "Octreotide-mediated tumor-targeted drug delivery via a cleavable doxorubicin–peptide conjugate", Mol. Pharm, 12, pp.4290~4300 (2015)
79. Hou, J., "RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy", Int J. Pharm, 505, pp.329~340 (2016)
80. Gilad, Y., "Dual-drug RGD conjugates provide enhanced cytotoxicity to melanoma and non-small lung cancer cells", Pept. Sci, 106, pp.160~171 (2016)
81. Fan, M., "Design and biological activity of epidermal growth factor receptortargeted peptide doxorubicin conjugate", Biomed. Pharmacother, 70, pp.268~273 (2015)
82. Regina, A., "Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2", Br. J. Pharm, 155, pp.185~197 (2008)
83. Topalian, S. L., "Neoadjuvant checkpoint blockade for cancer immunotherapy", Science, 367, pp.eaax0182~ (2020)
84. Valk, E., "CTLA-4 trafficking and surface expression", Trends Immunol, 29, pp.272~279 (2008)
85. Krummel, M. F., "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation", J. Exp. Med, 182, pp.459~465 (1995)
86. Bagchi, S., "Immune checkpoint inhibitors for the treatment of cancer : clinical impact and mechanisms of response and resistance", Annu Rev. Pathol, 16, pp.223~249 (2021)
87. Zou, W., "PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations", Sci. Transl. Med, 8, pp.328rv324~328rv324 (2016)
88. Yi, M., "Regulation of PD-L1 expression in the tumor microenvironment", J. Hematol. Oncol, 14, pp.1~13 (2021)
89. Dong, P., "Tumor-intrinsic PDL1signaling in cancer initiation, development and treatment : beyond immune evasion", Front Oncol, 8, pp.386~ (2018)
90. Nguyen, L. T., "Clinical blockade of PD1 and LAG3—potential mechanisms of action", Nat. Rev. Immunol, 15, pp.45~56 (2015)
91. Topalian, S. L., "Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy", Nat. Rev. Cancer, 16, pp.275~287 (2016)
92. Tremblay-LeMay, R., "Modulating PD-L1 expression in multiple myeloma : an alternative strategy to target the PD-1", PD-L1 pathway, 2018, pp.11, 1~16
93. Li, X. -S., "Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis", Biosci. Rep, 40, pp.BSR20200459~ (2020)
94. Surmiak, E., "PD-L1 inhibitors : different classes, activities, and mechanisms of action", Int J. Mol. Sci, 22, pp.11797~ (2021)
95. Li, C., "Peptide blocking of PD-1", PD-L1 interaction for cancer immunotherapy effect of PD-L1–targeting peptide on cancer immunotherapy, 2018, pp.6, 178~188
96. Magiera-Mularz, K., "Bioactive macrocyclic inhibitors of the PD-1", PD-L1immune checkpoint, 2017, pp.56, 13732~13735
97. Caldwell, C., "Identification and validation of a PD-L1 binding peptide for determination of PDL1 expression in tumors", Sci. Rep, 7, pp.1~11 (2017)
98. Liu, H., "Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy", J. Immunother. Cancer, 7, pp.1~14 (2019)
99. Yilei Chen, "Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy", Cancer Research and Treatment, 54(2), pp.362~374 (2022), 대한암학회[DOI]
100. Abbas, A. B., "Design and synthesis of A PD-1 binding peptide and evaluation of its anti-tumor activity", Int J. Mol. Sci, 20, pp.572~ (2019)
101. Gurung, S., "Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression", Biomaterials, 247, pp.119984~ (2020)
102. Moon, Y., "Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death", Theranostics, 12, pp.1999~ (2022)
103. Jeon, I. S., "Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs", Biomaterials, 270, pp.120685~ (2021)
104. Zhong, T., "The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo", Cancer Chemother. Pharm, 86, pp.783~792 (2020)
105. Zhai, W., "A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses", Acta Pharm. Sin. B, 10, pp.1047~1060 (2020)
106. Zhou, X., "A novel d‐peptide identified by mirror‐image phage display blocks TIGIT", PVR for cancer immunotherapy, 2020, pp.999(59), 15114~15118
107. Ma, P. C., "c-Met : structure, functions and potential for therapeutic inhibition", Cancer Metastasis Rev, 22, pp.309~325 (2003)
108. Xia, C., "Novel Peptide CM 7 Targeted c-met with antitumor activity", Molecules, 25, pp.451~ (2020)
109. Tam, E. M., "Noncompetitive inhibition of hepatocyte growth factordependent Met signaling by a phage-derived peptide", J. Mol. Biol, 385, pp.79~90 (2009)
110. Shen, Y., "Discovery of HB-EGF binding peptides and their functional characterization in ovarian cancer cell lines", Cell Death Disco, 5, pp.1~11 (2019)
111. Yan, Y., "Concise review : emerging role of CD44 in cancer stem cells : a promising biomarker and therapeutic target", Stem Cells Transl. Med, 4, pp.1033~1043 (2015)
112. Matzke, A., "A five-amino-acid peptide blocks Met-and Ron-dependent cell migration", Cancer Res, 65, pp.6105~6110 (2005)
113. Matzke-Ogi, A., "Inhibition of tumor growth and metastasis in pancreatic cancer models by interference with CD44v6 signaling", Gastroenterol, 150, pp.513~525 (2016)
114. Chalmin, F., "Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells", J. Clin. Invest, 120, pp.457~471 (2010)
115. Gobbo, J., "Restoring anticancer immune response by targeting tumorderived exosomes with a HSP70 peptide aptamer", J. Natl Cancer Inst, 108, pp.djv330~ (2016)
116. Stamatiades, G. A., "Gonadotropin regulation by pulsatile GnRH : signaling and gene expression", Mol. Cell Endocrinol, 463, pp.131~141 (2018)
117. -luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma, "Cancer Res", 1990, 1841~1846
118. Tieva, Å., "Gonadotropinreleasing hormone receptor expression in the human prostate", Prostate, 47, pp.276~284 (2001)
119. Huerta-Reyes, M., "Treatment of breast cancer with gonadotropin-releasing hormone analogs", Front Oncol, 9, pp.943~ (2019)
120. Lu, Y. -S., "Ovarian function suppression with luteinizing hormone-releasing hormone agonists for the treatment of hormone receptorpositive early breast cancer in premenopausal women", Front Oncol, 11, pp.700722~ (2021)
121. Di Lauro, L., "Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer : results from a pooled analysis", J. Hematol. Oncol, 8, pp.1~5 (2015)
122. Hofland, L. J., "Somatostatin receptors and disease : role of receptor subtypes", Baillieres Clin. Endocrinol. Metab, 10, pp.163~176 (1996)
123. Druker, B. J., "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome", N. Eng. J. Med, 344, pp.1038~1042 (2001)
124. Gurung, A., "Binding of small molecules at interface of protein–protein complex–A newer approach to rational drug design", Saudi J. Biol. Sci, 24, pp.379~388 (2017)
125. Ran, X., "Inhibitors of protein–protein interactions(PPIs) : an analysis of scaffold choices and buried surface area", Curr. Opin. Chem. Biol, 44, pp.75~86 (2018)
126. Mason, J. M., "iPEP: peptides designed and selected for interfering with protein interaction and function", Biochem. Soc. Trans, 36, pp.1442~1447 (2008)
127. Bruno, B. J., "Basics and recent advances in peptide and protein drug delivery", Ther. Deliv, 4, pp.1443~1467 (2013)
128. Chen, X., "Fusion protein linkers: property, design and functionality", Adv. Drug Deliv. Rev, 65, pp.1357~1369 (2013)
129. Sikora, K., "c-myc oncogene expression in colorectal cancer", Cancer, 59, pp.1289~1295 (1987)
130. Little, C. D., "Amplification and expression of the c-myc oncogene in human lung cancer cell lines", Nature, 306, pp.194~196 (1983)
131. Blackwood, E. M., "Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc", Science, 251, pp.1211~1217 (1991)
132. Li, L., "Time-staggered delivery of docetaxel and H1-S6A, F8A peptide for sequential dual-strike chemotherapy through tumor priming and nuclear targeting", J. Control Release, 232, pp.62~74 (2016)
133. Bidwell, G. L. III, "Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model", PloS one, 8, pp.e55104~ (2013)
134. Soucek, L., "Design and properties of a Myc derivative that efficiently homodimerizes", Oncogene, 17, pp.2463~2472 (1998)
135. Soucek, L., "Omomyc expression in skin prevents Myc-induced papillomatosis", Cell Death Differ, 11, pp.1038~1045 (2004)
136. Soucek, L., "Modelling Myc inhibition as a cancer therapy", Nature, 455, pp.679~683 (2008)
137. Krumlauf, R., "Hox genes in vertebrate development", Cell, 78, pp.191~201 (1994)
138. Bhatlekar, S., "Overexpression of HOXA4 and HOXA9 genes promotes self-renewal and contributes to colon cancer stem cell overpopulation", J. Cell Physiol, 233, pp.727~735 (2018)
139. Morgan, R., "Antagonism of HOX", PBX dimer formation blocks the in vivo proliferation of melanoma, 2007, pp.67, 5806~5813
140. Shen, W. -F., "Hox homeodomain proteins exhibit selective complex stabilities with Pbx and DNA", Nucleic Acids Res, 24, pp.898~906 (1996)
141. Neuteboom, S., "Pbx raises the DNA binding specificity but not the selectivity of antennapedia Hox proteins", Mol. Cell Biol, 17, pp.4696~4706 (1997)
142. Plowright, L., "HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer(targeting HOX genes in lung cancer)", Br. J. Cancer, 100, pp.470~475 (2009)
143. Moore, A. R., "RAS-targeted therapies:is the undruggable drugged?", Nat. Rev. Drug Disco, 19, pp.533~552 (2020)
144. Huang, L., "KRAS mutation : from undruggable to druggable in cancer", Signal Transduct. Target Ther, 6, pp.1~20 (2021)
145. Garrigou, M., "Accelerated identification of cell active KRAS inhibitory macrocyclic peptides using mixture libraries and automated ligand identification system(ALIS)technology", J. Med. Chem, 65, pp.8961~8974 (2022)
146. Lim, S., "Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling", Chem. Sci. J, 12, pp.15975~15987 (2021)
147. Lee, Y., "Targeted Degradation of Transcription Coactivator SRC-1 through the N-Degron Pathway", Angew. Chem. Int Ed. Engl, 59, pp.17548~17555 (2020)
148. Choi, S. R., "Hydrophobic tagging-mediated degradation of transcription coactivator SRC-1", Int J. Mol. Sci, 22, pp.6407~ (2021)

관련 논문AI추천